#United States #Natick #Medicare #Pillar Biosciences #oncoReveal CDx

Pillar Biosciences Confirms Medicare Pricing for oncoReveal CDx

In a significant advancement for cancer diagnostics, Pillar Biosciences, known for its expertise in Decision Medicine™, has reported the final pricing determination for its innovative diagnostic tool, the oncoReveal® CDx. Announced on December 1, 2025, this decision by the Centers for Medicare & Medicaid Services (CMS) marks a crucial step towards ensuring that patients can benefit from precise cancer testing.

Following CMS's preliminary decision made in August 2025, the confirmed payment rate is set at $1,352.09, applicable for claims filed on or after January 1, 2026. This crosswalk-based payment structure intends to enhance the diagnostic options available to Medicare beneficiaries, an essential group particularly in need of advanced cancer care.

Benefits of oncoReveal CDx

Gang Song, the company’s founder and CEO, expressed satisfaction with the CMS's decision, asserting that this pricing will facilitate greater accessibility to high-quality cancer diagnostics. The oncoReveal CDx represents a landmark innovation in the medical field as it is the first PMA-approved multi-cancer in vitro diagnostic (IVD) kit available in the United States. It provides highly accurate, actionable results derived from next-generation sequencing (NGS) technology.

Brian Wright, Chief Marketing Officer at Pillar Biosciences, highlighted the importance of this milestone. With over 66 million Americans covered by Medicare, the new pricing is poised to significantly broaden patient access to precision oncology testing, a field that has continually evolved to offer improved outcomes for cancer patients.

The Importance of Precision Oncology

Precision oncology refers to tailored cancer treatment strategies based on the genetic makeup of the individual’s tumor. By using advanced tools such as oncoReveal CDx, healthcare providers can better determine the most effective therapies for their patients, enhancing the chances of successful outcomes. The innovation in diagnostics brought by Pillar Biosciences not only underscores the importance of advanced medicine in treating complex diseases like cancer but also reflects a wider trend towards personalized patient care.

About Pillar Biosciences

Pillar Biosciences is at the forefront of Decision Medicine™, focusing on making complex molecular testing more accessible and cost-effective. The company utilizes proprietary technologies like SLIMamp® and PiVAT® to streamline diagnostic processes, resulting in lower costs and improved patient accessibility to necessary diagnostic evaluations. Currently, it offers more than 20 NGS testing kits in both regulatory and research-use formats, with promising expansions planned for the near future.

Headquartered in Natick, Massachusetts, Pillar Biosciences remains dedicated to transforming the landscape of cancer diagnostics and treatment. For more information about their services and innovations, visit Pillar Biosciences’ website or follow them on LinkedIn.

Conclusion

The finalized pricing determination for oncoReveal CDx is an essential development that signals progress in the fight against cancer. With Medicare support, Pillar Biosciences is set to empower healthcare providers and patients alike with enhanced tools for diagnosis and treatment, setting a new standard in oncology care.